

## Guidelines for Infection Prevention and Control in Sonography:

### Reprocessing the Ultrasound Transducer

1 **Endorsing Organizations**

- 2 •
- 3 •
- 4 •

6 **Supporting Organizations\***

- 7 •
- 8 •
- 9 •

11 \* Some organizations have internal policies that do not permit endorsement of external documents. "Supporting  
 12 organization" denotes a more limited level of review and approval than endorsement and means the organization  
 13 considers the clinical document to be of educational value, although it may not agree with every recommendation  
 14 or statement in the document.

16 Rev. ??/??/????

22 **DISCLAIMER:** THE SOCIETY OF DIAGNOSTIC MEDICAL SONOGRAPHY (SDMS) AND THE SDMS  
 23 SONOGRAPHY DISINFECTION & INFECTION CONTROL TASK FORCE MEMBERS RECEIVED NO PAYMENT OR  
 24 OTHER INDUCEMENTS FOR THE DEVELOPMENT OF THE GUIDELINES FOR INFECTION PREVENTION AND  
 25 CONTROL IN SONOGRAPHY: REPROCESSING THE ULTRASOUND TRANSDUCER. THE TASK FORCE MEMBERS  
 26 PROVIDED THE SDMS WITH CONFLICT OF INTEREST DISCLOSURES.

28 A NUMBER OF ORGANIZATIONS AND INDUSTRY PARTNERS HAVE PROVIDED LOGISTICAL SUPPORT TO THE  
 29 SDMS, INCLUDING BUT NOT LIMITED TO, GATHERING RELEVANT STANDARDS, RESEARCH, AND ARTICLES.  
 30 NONE HAVE PARTICIPATED IN OR INFLUENCED THE SDMS SONOGRAPHY DISINFECTION & INFECTION  
 31 CONTROL TASK FORCE’S CONSIDERATION OF SUCH DOCUMENTS NOR HAD INVOLVEMENT IN THE TASK  
 32 FORCE MEETINGS OR ITS DEVELOPMENT OF THESE GUIDELINES.

34 THIS DOCUMENT IS PROVIDED WITHOUT ANY REPRESENTATIONS OR WARRANTIES, EXPRESS OR IMPLIED.  
 35 THE AUTHORS AND ALL PARTICIPATING, SUPPORTING, AND ENDORSING ORGANIZATIONS EXPRESSLY  
 36 DISCLAIM ALL LIABILITY TO ANY PARTY FOR THE ACCURACY, COMPLETENESS, OR AVAILABILITY OF THIS  
 37 DOCUMENT, OR FOR DAMAGES ARISING OUT OF THE USE OF THIS DOCUMENT AND ANY INFORMATION  
 38 IT CONTAINS.

43 © Copyright 2017-2019. Society of Diagnostic Medical Sonography, Plano, Texas. All Rights Reserved.  
 44 Permission for redistribution of the final document in its entirety is hereby granted.

46 SCOPE..... 1

47 DEVELOPMENT PROCESS..... 2

48 ACKNOWLEDGEMENTS ..... 2

49 1. INTRODUCTION ..... 3

50 2. INFECTION PREVENTION AND CONTROL RISKS AND CHALLENGES ..... 3

51 3. UNDERSTANDING HOW THE SPAULDING CLASSIFICATION AFFECTS TRANSDUCER REPROCESSING..... 4

52 3.1. ASSIGNING THE SPAULDING CLASSIFICATION BASED ON INTENDED USE .....5

53 4. SONOGRAPHIC PROCEDURE..... 5

54 4.1. BEFORE THE PROCEDURE .....5

55 4.1.1. *Select the Correct Transducer*.....5

56 4.1.2. *Select the Correct Transducer Cover*.....6

57 4.1.3. *Select the Correct Ultrasound Gel*.....6

58 4.2. DURING THE PROCEDURE.....6

59 4.3. AFTER THE PROCEDURE .....7

60 5. TRANSDUCER REPROCESSING ..... 7

61 5.1. CLEANING.....7

62 5.2. DISINFECTION AND STERILIZATION .....7

63 5.2.1. *Sterilization*.....7

64 5.2.2. *High-Level Disinfection (HLD)* .....8

65 5.2.3. *Low-Level Disinfection (LLD)*.....8

66 5.3. RINSING AND DRYING .....8

67 5.4. DOCUMENTATION AND TRACEABILITY .....9

68 5.5. STORAGE .....9

69 6. INFECTION PREVENTION AND CONTROL CONSIDERATIONS FOR TRANSDUCER REPROCESSING WORKFLOW9

70 6.1. TYPES OF PROCEDURES.....9

71 6.2. REPROCESSING TIME.....9

72 6.3. REPROCESSING LOCATION.....10

73 6.4. COMPATIBILITY .....10

74 6.5. COST, COMPLEXITY, AND SAFETY.....10

75 6.6. ESTABLISHING POLICIES AND STANDARD OPERATING PROCEDURES (SOPs) .....10

76 6.7. PERSONNEL.....10

77 6.8. EVALUATION AND QUALITY IMPROVEMENT .....10

78 7. REFERENCES ..... 12

79 8. GLOSSARY OF TERMS AND ABBREVIATIONS/ACRONYMS .....14

80

## 81 Scope

82 The diagnostic medical sonography profession is comprised of specialties in abdominal, breast, cardiac,  
83 obstetrics, gynecology, pediatric, phlebology, vascular, and other emerging clinical areas. These diverse  
84 areas of sonography all use ultrasound as the primary technology in their daily work.

85 Sonographers have a responsibility to ensure that the ultrasound transducer (“transducer”) and other  
86 equipment used are properly reprocessed. These guidelines specifically address reprocessing (e.g.,  
87 cleaning, disinfection or sterilization, transport, and storage) of transducers used in diagnostic medical  
88 sonography, but not those used for endoscopic, intracardiac, intravascular, or laparoscopic purposes.

89 Because of the sensitivity of the transducer’s materials and electronics to some sterilization techniques,  
90 gaps may exist in the ability to perform the desired method of sterilization for the transducer. Therefore,  
91 while these guidelines address current best practices, users of these guidelines should recognize that best  
92 practices will evolve over time based on technological advances and new research.

93 To ensure the facility has the capability and capacity to adequately clean and reprocess the transducer,  
94 sonographers should obtain and review the manufacturer’s Instructions for Use (IFU) or other guidance  
95 on use, handling, cleaning, disinfection or sterilization, transport, and storage of the manufacturer’s  
96 equipment before purchasing. Manufacturers and suppliers should ensure guidance on use, handling,  
97 cleaning, disinfection or sterilization, transport, and storage specific to each machine, transducer, or other  
98 equipment is easily accessible on their website. Manufacturers and companies that refurbish transducers  
99 should take the steps necessary to prevent contamination during or after the manufacturing or  
100 refurbishment process. However, regardless of the source, a newly acquired, non-sterile transducer  
101 should be processed as if it was used previously.

102 While these guidelines focus on the reprocessing of the transducer, the importance of infection  
103 prevention and control principles apply equally to the ultrasound machine and any ancillary equipment  
104 used during the procedure (e.g., cables, keyboards, gel bottle, beds, chairs, IV poles, oxygen systems, light  
105 switches, door knobs/handles). Cross-contamination of the ultrasound machine and any ancillary  
106 equipment presents significant infection prevention and control risks and challenges. Where applicable,  
107 refer to the manufacturer’s IFU or the facility’s policies for the proper cleaning, disinfection or sterilization,  
108 transport, and storage (as applicable) for ultrasound machines, transducers, and any ancillary equipment.  
109 New technologies (e.g., transducers connected to smartphones or tablets) will add new risks and  
110 challenges that the manufacturer, facilities, and sonographers must address in the future.

111 **NOTE:** These guidelines apply only to transducers used to scan humans and not those used to scan  
112 animals. A sonographer should never use a transducer on a human that has been used on an animal,  
113 regardless of the subsequent cleaning, disinfection, or sterilization level.

114

## 115 Development Process

116 At the end of 2017, the Society of Diagnostic Medical Sonography’s (SDMS) Sonography Disinfection &  
117 Infection Control Task Force developed draft guidelines consistent with existing regulations, standards,  
118 and current best practices. In early 2018, the Task Force shared the draft with sonography and infection  
119 prevention and control-related organizations and manufacturers for input. The Task Force met to finalize  
120 the second draft in early 2019 and shared the second draft with sonography and infection control-related  
121 organizations and manufacturers for input. The Task Force will distribute the final guidelines for  
122 organizational endorsement or support.

123 **Note:** *Some organizations have internal policies that do not permit endorsement of external*  
124 *documents. Therefore, notation as a “supporting organization” will denote a more limited level of*  
125 *review and approval than endorsement and means the organization considers the clinical document*  
126 *to be of educational value, although it may not agree with every recommendation or statement.*  
127  
128

## 129 Acknowledgements

### 130 SDMS Sonography Disinfection & Infection Control Task Force (2017-2019)

- 131 • Jennifer Bagley, MPH, RDMS, RVT, FAIUM (Chair)
- 132 • Roy Boukidjian, MSN, PHN, CIC, NE-BC
- 133 • Ruth Carrico, PhD, DNP, FNP-C, CIC, FSHEA
- 134 • Mary Whitsett, BS, RDMS, RVT, RT(R)(T)
- 135 • Talisha Hunt, BSRT, RDMS, RDCS, RVT (Board Liaison)
- 136 • Don Kerns, JD, CAE (Staff Liaison)
- 137 • Mary Rodriguez, BS, CAE (Staff Liaison)

138

## 139 1. Introduction

140 Sonography is a safe and effective imaging modality widely used across various inpatient and outpatient  
141 settings for the performance of a variety of procedures and diagnostic imaging. Evidence-based and  
142 reproducible infection prevention and control practices are essential to ensure that sonography  
143 procedures are safe for patients and sonographers. Infection prevention and control guidelines and  
144 standards covering sonography have been in place for many years in the United States, but pre-date the  
145 rapid expansion of the use of sonography in many medical specialties and procedures.

146 In particular, those guidelines and standards incorporate the Centers for Disease Control and Prevention  
147 (CDC) *Guidelines for Disinfection and Sterilization in Healthcare Facilities* (published in 2008, reviewed in  
148 2017), the Association for the Advancement of Medical Instrumentation (AAMI) standard *ST58:2013:*  
149 *Chemical Sterilization and High-Level Disinfection in Healthcare Facilities*, the Food and Drug  
150 Administration (FDA), and the AAMI standard *ST34:2014: Water for the Reprocessing of Medical Devices,*  
151 *and the Spaulding Classification.*<sup>1-5</sup> Other transducer reprocessing guidelines have also been released,  
152 both in the United States and internationally, including from the following organizations: American  
153 Institute for Ultrasound in Medicine, World Federation for Ultrasound in Medicine and Biology, European  
154 Society of Radiology, European Committee for Medical Ultrasound Safety, Australasian Society for  
155 Ultrasound in Medicine/Australasian College for Infection Prevention and Control, Health Service  
156 Executive Ireland and Health Facilities Scotland.<sup>6-12</sup>

157 This document builds upon earlier guidelines and provides a comprehensive set of recommendations that  
158 any sonographer can use to answer disinfection and transducer reprocessing questions or to implement  
159 the recommendations.

## 160 2. Infection Prevention and Control Risks and Challenges

161 Proper infection prevention and control practices are necessary to protect patients and sonographers.  
162 Contaminated transducers and gel have been associated with infection outbreaks, including those in the  
163 bloodstream, urinary tract, respiratory tract, biopsy sites, and wounds. There are also documented cases  
164 of hepatitis B and C with some resulting in patient death.<sup>13-19</sup> These infections were attributable to a  
165 failure to follow evidence-based and reproducible infection prevention and control practices (e.g., proper  
166 transducer cleaning and disinfection, appropriate transducer cover, sterile gel). As a result, regulatory,  
167 accrediting, and public health agencies, including the FDA, The Joint Commission, and the CDC have issued  
168 several alerts regarding transducer use and reprocessing.<sup>20-22</sup>

169 Several studies suggest that bacteria and other pathogens that may be resistant to some disinfectants  
170 including glutaraldehyde and ortho-phthalaldehyde (OPA) can contaminate the transducer.<sup>9,23</sup> Use of a  
171 properly disinfected transducer, transducer cover, and sterile gel can reduce the risk of transmitting  
172 bacteria and other pathogens during sonographic procedures and promote patient safety.

173

### 174 3. Understanding How the Spaulding Classification Affects Transducer 175 Reprocessing

176 The Spaulding Classification determines the disinfection and sterilization requirements for medical  
177 devices based on the level of infection risk associated with their use.<sup>5</sup> Medical device reprocessing  
178 standards, regulations, and guidelines widely use this classification system.<sup>1,2,24-26</sup> For example, the CDC  
179 guidelines categorize medical devices reprocessing requirements based on risk using the Spaulding  
180 Classification (Table 1).

181 The intended use of the transducer in the procedure determines its classification into one of three groups:

182 **Critical** – Transducer contacts sterile tissues or a device (e.g., needle, catheter) inserted into  
183 sterile tissue during the procedure. Sterile tissue includes body sites, cavities, or tissues that are  
184 endogenously free from all living organisms. This would include the vascular system, joints and  
185 joint spaces, other internal body fluids such as blood or synovial fluid, the vasculature, internal  
186 body organs, peritoneum, and retroperitoneum.

187 **Semi-critical** – Transducer contacts mucous membranes or non-intact skin or a device that  
188 contacts mucous membranes or non-intact skin during the procedure (i.e., no risk of contact with  
189 sterile tissues). Mucous membranes produce mucus and line cavities or surfaces of the body that  
190 open to the external environment, such as the digestive tract, the respiratory passages, and the  
191 genitourinary tract. Non-intact skin includes cuts, punctures, abrasions, dermatitis, etc.

192 **Non-critical** – Transducer only contacts intact skin, or a device used during the procedure that  
193 contacts intact skin (i.e., no risk of contact with sterile tissues, mucous membranes, or non-intact  
194 skin). Intact skin is completely healthy and does not have open cuts, punctures, abrasions,  
195 dermatitis, etc.

196 It is the nature of the procedure itself that determines the transducer’s status as critical, semi-critical, or  
197 non-critical and the sonographer may classify the same transducer differently when it is used in another  
198 procedure. Each Spaulding Classification has different disinfection and sterilization requirements (Table  
199 1).

200 Use of a transducer cover does not change the Spaulding Classification or disinfection process as  
201 transducer covers have been shown to have micro-perforations and they can break, open, or tear.<sup>1,26</sup> Any  
202 ancillary equipment used in conjunction with the transducer should also be disinfected based on the type  
203 of equipment, manufacturer’s IFU, and other available guidance.

204

205 **Table 1. How the Spaulding Classification Affects Transducer Reprocessing**  
 206 **(adapted from the CDC guidelines<sup>1</sup>)**

Risk Associated with Intended Use	Spaulding Classification	Disinfection/ Sterilization Level Required <sup>#</sup>
Transducer contacts sterile tissues or a device (e.g., needle, catheter) inserted into sterile tissue during the procedure.	Critical	Cleaning followed by sterilization. If sterilization is not possible, then use high-level disinfection (HLD) and a sterile transducer cover. <sup>1</sup>
Transducer contacts mucous membranes or non-intact skin or a device that contacts mucous membranes or non-intact skin during the procedure (i.e., no risk of contact with sterile tissues).	Semi-critical	Cleaning followed by HLD
Transducer only contacts intact skin, or a device used during the procedure that contacts intact skin (i.e., no risk of contact with sterile tissues, mucous membranes, or non-intact skin).	Non-critical	Cleaning followed by low-level disinfection (LLD)

207 HLD = high-level disinfection, LLD = low-level disinfection.

208 <sup>#</sup>See section 5.2 for definitions of sterilization, high-level disinfection, and low-level disinfection.

209 **3.1. Assigning the Spaulding Classification Based on Intended Use**

210 Make the Spaulding Classification determination before the procedure commences. It is sometimes  
 211 difficult to anticipate what tissues or devices the transducer might contact (e.g., catheter, sterile tissue,  
 212 mucous membranes, intact, or non-intact skin).

213 Where some risk of contact exists, apply the higher classification. For example, a procedure to guide a  
 214 tissue biopsy is as a critical procedure due to the increased risk that the transducer might contact the  
 215 needle inserted into the sterile tissue.

216 **4. Sonographic Procedure**

217 Refer to the steps below to prevent infection transmission in conjunction with performing the procedure.

218 **4.1. Before the Procedure**

219 Ensure the procedure area is clean and surfaces have been appropriately disinfected, the transducer has  
 220 been appropriately reprocessed, and any necessary ancillary equipment is clean for the upcoming  
 221 procedure.

222 **4.1.1. Select the Correct Transducer**

223 Determine the correct transducer for the procedure, visually inspect the transducer (e.g., damage, visible  
 224 soil, bioburden), and prepare the transducer based on the Spaulding Classification guidance regarding the  
 225 procedure. If the patient’s circumstances unexpectedly change before or during the procedure, ensure  
 226 that the selected transducer is still appropriate based on the reassessment of the procedure and its  
 227 alignment with the Spaulding Classification.



#### 228 4.1.2. Select the Correct Transducer Cover

229 The choice of transducer cover will depend on the procedure to be performed. For critical procedures, a  
 230 transducer cover is optional with a sterilized transducer, but a sterile transducer cover should be used  
 231 with a high-level disinfected transducer.<sup>1</sup> At the minimum, use a non-sterile transducer cover for all semi-  
 232 critical procedures (e.g., endocavitary); however, a sterile cover is preferred. Transducer covers are  
 233 optional for non-critical procedures. Do not reuse transducer covers.

234 If during the procedure the transducer cover is damaged (e.g., tear, puncture), immediately discard the  
 235 damaged transducer cover and replace the contaminated transducer with an appropriately disinfected  
 236 transducer and new transducer cover. After the procedure, inspect the contaminated transducer for  
 237 possible damage.

238 **Table 2. Transducer Cover Selection Based on the Spaulding Classification**

Spaulding Classification	Transducer Cover
Critical	Sterilized transducer (preferred) or a sterile cover with an HLD transducer
Semi-critical	Sterile cover (preferred) or non-sterile cover
Non-critical	Optional

#### 239 4.1.3. Select the Correct Ultrasound Gel

240 A single-use, sterile gel packet is recommended for all critical procedures and is preferable for semi-critical  
 241 procedures.<sup>6,12</sup> A single use, non-sterile gel packet is recommended for all semi-critical procedures and is  
 242 preferred for non-critical procedures. Do not use a multi-use gel bottle for critical and semi-critical  
 243 procedures. A multi-use gel bottle is the least preferred option for non-critical procedures due to the  
 244 potential for patient cross-contamination and gel contamination.

245 **Table 3. Ultrasound Gel Selection Based on the Spaulding Classification**

Spaulding Classification	Ultrasound Gel
Critical	Single-use, sterile gel only
Semi-critical	Single-use, sterile gel (preferred) or single-use, non-sterile gel
Non-critical	Single-use, non-sterile gel (preferred) or multi-use non-sterile gel (i.e., bottle)

246 Discard unused portions of a single-use gel packet; do not use on other patients. If using a multi-use gel  
 247 bottle, ensure the tip of a multi-use gel bottle does not come in contact with the patient, transducer, and  
 248 any ancillary equipment. If the multi-use gel bottle tip comes in contact, discard the multi-use gel bottle.  
 249 If a multi-use gel bottle is used with an isolation patient or in an isolation precaution setting, discard the  
 250 multi-use gel bottle.

251 The use of a refilled gel bottle as well as heating of gel is discouraged, as this can lead to microorganism  
 252 growth, pathogen transmission, cross-contamination, and possible outbreaks.<sup>27</sup>

#### 253 4.2. During the Procedure

254 During the procedure, use techniques that prevent the transfer of pathogens from potential contaminated  
 255 surfaces (e.g., clothing, non-sterile gloves, other equipment, and environment) to the disinfected  
 256 transducer, transducer cover, or gel.

#### 257 4.3. After the Procedure

258 After the procedure, remove the transducer cover (if used) from the transducer and discard in a  
259 designated, approved receptacle. Immediately clean the transducer (e.g., remove any remaining gel,  
260 visible soil, or bioburden), place it in a transport container (e.g., container with lid, impermeable bag),  
261 label container as dirty with a biohazard symbol, and deliver it to the reprocessing area. Clean and  
262 disinfect all high-touch surfaces in the procedure area including, but not limited to bed railings and the  
263 ultrasound machine’s console and controls (see the manufacturer’s IFU or other guidance). Discard waste  
264 (e.g., used gloves, wipes, drapes) in a designated, approved receptacle.

### 265 5. Transducer Reprocessing

266 According to the CDC *Guidelines for Disinfection and Sterilization in Healthcare Facilities*, there are various  
267 factors that affect the efficacy of reprocessing including: prior cleaning, removal of bioburden, the organic  
268 and inorganic load that is present, type and degree of microbial contamination, concentration and  
269 exposure time of the germicide, and the physical features of the transducer or equipment (bevels,  
270 crevices, lumens, etc). Additionally, temperature and pH of the process and relative humidity may affect  
271 the sterilization process.<sup>1</sup>

272 Reprocess the transducer and any ancillary equipment used between each patient use. Reprocessing  
273 refers to the procedure undertaken to prepare an instrument for reuse. The reprocessing phases include  
274 cleaning, disinfection or sterilization, transport, and storage. Additional considerations such as traceability  
275 are also important. See details below.

#### 276 5.1. Cleaning

277 Effective disinfection or sterilization requires adequate cleaning. Cleaning should remove all visible gel,  
278 soil, and bioburden on all surfaces of the transducer or any ancillary equipment including any indentations  
279 or complex surfaces. Potential cleaning agents for the transducer include neutral pH cleaner, approved  
280 wipes, soap and running water, and enzyme soaks. Selection of a cleaning process should factor in cleaning  
281 efficacy, cost, time, complexity, safety, designated location for reprocessing, and the transducer  
282 manufacturer’s IFU.

#### 283 5.2. Disinfection and Sterilization

284 Disinfection or sterilization refers to the destruction or inactivation of microorganisms, which in turn  
285 minimizes infection transmission risk. Choice of disinfection or sterilization level depends on the Spaulding  
286 Classification of the transducer or other ancillary equipment, which is based on use in the prior completed  
287 procedure and the intended use in the next procedure. Use of a transducer cover does not change the  
288 Spaulding Classification since transducer covers have been shown to leak or tear.<sup>1</sup> Transducer  
289 manufacturer’s IFUs should be consulted for the recommended disinfection or sterilization methods.  
290 Other factors to consider include disinfection or sterilization efficacy, cost, cycle time, complexity, safety,  
291 designated location, simultaneous transducer reprocessing capability, and the transducer manufacturer’s  
292 IFU. See below for further detail on sterilization, high-level disinfection, and low-level disinfection.

##### 293 5.2.1. Sterilization

294 The FDA defines sterilization as the complete removal of all viable microorganisms, including bacterial  
295 endospores, to the extent of achieving a sterility assurance level (SAL) of at least  $10^{-6}$ .<sup>3</sup> Ideally, all critical  
296 transducers and devices that are to be inserted into sterile tissue (e.g., needles, catheters) would be  
297 sterilized. However, if the transducer cannot be sterilized (e.g., per the manufacturer’s IFU), HLD is

298 acceptable if the transducer is used in conjunction with a sterile transducer cover and sterile gel.<sup>1,12</sup>  
299 Common sterilization options for the transducer include ethylene oxide gas, hydrogen peroxide gas  
300 plasma, and liquid chemicals with extended contact times (e.g., glutaraldehyde, ortho-phthalaldehyde).<sup>2</sup>  
301 It is critical to ensure that any sterilization process is compatible with the transducer and will not cause  
302 damage (see manufacturer’s IFU).

### 303 5.2.2. High-Level Disinfection (HLD)

304 HLD is the removal of all microorganisms except bacterial endospores, of which small numbers are  
305 permitted to remain.<sup>1,6-8,12</sup> HLD is required for a semi-critical transducer that contacts mucous membranes  
306 or non-intact skin and any device used during the procedure that contacts mucous membranes, non-intact  
307 skin, or the transducer. HLD is also suitable for a critical transducer in the event they cannot be sterilized,  
308 as long as the transducer is used with a sterile transducer cover.<sup>1,12</sup>

309 According to the CDC *Guidelines for Disinfection and Sterilization in Healthcare Facilities*, unlike  
310 sterilization, disinfection is not sporicidal. A few disinfectants, known as chemical sterilants, will kill spores  
311 with prolonged exposure times (3–12 hours). At similar concentrations but with shorter exposure periods  
312 (e.g., 20 minutes for 2% glutaraldehyde), these same disinfectants are called high-level disinfectants and  
313 will kill all microorganisms except large numbers of bacterial spores.<sup>1</sup>

314 Automated HLD methods include hydrogen peroxide mist devices and liquid soak devices using approved  
315 liquid chemicals such as glutaraldehyde, ortho-phthalaldehyde, and accelerated hydrogen peroxide.  
316 Manual HLD can safely occur using HLD vapor control soaking stations with approved liquid chemicals  
317 such as glutaraldehyde, ortho-phthalaldehyde, peracetic acid, hydrogen peroxide, and accelerated  
318 hydrogen peroxide. Automated processes are preferable due to the reduced risk of operator error.<sup>7,12,28,29</sup>

319 Select HLD methods that are efficient, effective, reliable, reproducible, and safe for the transducer,  
320 sonographer, and environment. A process that high-level disinfects the transducer (head and handle) in  
321 conjunction with low level disinfection of cables and connectors is preferred, as these components can  
322 harbor clinically relevant pathogens.<sup>23,30</sup> Refer to the manufacturer’s IFU to ensure that the HLD process  
323 selected is compatible with the transducer and for other suitable HLD options. Refer to the FDA’s website  
324 ([https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedical](https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm)  
325 [Devices/ucm437347.htm](https://www.fda.gov/MedicalDevices/DeviceRegulationandGuidance/ReprocessingofReusableMedicalDevices/ucm437347.htm)) for a list of liquid HLD disinfectant chemistries.

### 326 5.2.3. Low-Level Disinfection (LLD)

327 LLD is the inactivation of vegetative bacteria, enveloped viruses, some non-enveloped viruses, and most  
328 fungi in a practical period of time ( $\leq 10$  minutes).<sup>1</sup> LLD is used for a non-critical transducer that only  
329 contacts intact skin.<sup>1</sup> Common low-level disinfecting agents include quaternary ammonium compounds,  
330 alcohols, and phenols available as sprays and disinfectant wipes. Ensure that the chosen LLD disinfection  
331 method is compatible with the transducer. Alcohols are often contraindicated due to material  
332 incompatibility.

### 333 5.3. Rinsing and Drying

334 Perform rinsing and drying after disinfection or sterilization if required by the manufacturer’s IFU. This  
335 step may be necessary to ensure that no chemical residues remain on the transducer after reprocessing.  
336 Some automated processes may not require a rinsing step. Follow the disinfectant manufacturer’s IFU for  
337 rinse requirements, rinse water quality and sterility, the number of rinses, and drying method. Following  
338 HLD, perform the rinses in a separate clean container using critical water (treated water).<sup>4</sup> Sterile water  
339 is required for immunocompromised patients.<sup>1,2,4,31</sup>

#### 340 5.4. Documentation and Traceability

341 The facility should develop a written policy outlining the process for documentation and traceability.  
342 Documentation and traceability measures are needed for critical and semi-critical transducers requiring  
343 sterilization and HLD but may not be necessary for non-critical transducers requiring LLD.<sup>2</sup>

344 Document all reprocessing details including, but not limited to, the transducer model and serial number,  
345 reprocessing personnel identification (ID), cycle number, validation result (e.g. chemical indicator/test  
346 strip, temperature, soaking time), date/time, and patient identification.<sup>2</sup>

347 To ensure traceability, reprocessing records must be linked to the patient on whom the transducer is used.  
348 Traceability is ensured through manual (e.g., log books, stickers) or automated processes (e.g., electronic  
349 health record (EHR), RFID tracking systems). In the event of a reprocessing failure or an outbreak,  
350 complete documentation for each transducer reprocessing cycle will aid in traceability for patient trace-  
351 back.

#### 352 5.5. Storage

353 Store the reprocessed transducer properly to prevent re-contamination of the transducer before use.  
354 Suitable options for transducer storage include storage covers, boxes, or cabinets (e.g., HEPA-filtered,  
355 ventilated or non-ventilated). Proper storage reduces the risk of re-contamination of the transducer from  
356 environmental contaminants or accidental contamination during storage. Follow the manufacturer's IFU  
357 or other guidance for proper storage. Clearly label the container holding the transducer with disinfection  
358 level and date during storage to facilitate easy identification. Maintain distinct separation of clean and  
359 dirty transducers (e.g., dirty transducer not placed in the same cabinet as clean transducers). Conduct a  
360 risk assessment to determine the maximum storage duration for the transducer. Refer to the  
361 manufacturer's IFU regarding the maximum storage duration, if applicable, and any reprocessing  
362 requirements.

### 363 6. Infection Prevention and Control Considerations for Transducer 364 Reprocessing Workflow

365 There are many things to consider when establishing an infection prevention and control workflow for  
366 transducer reprocessing. Perform reprocessing with a dirty-to-clean workflow. See below for some  
367 considerations to assist in streamlining this process.

#### 368 6.1. Types of Procedures

369 Consider the type of procedure, location, and disinfection or sterilization requirements. In some clinical  
370 settings, the transducer may be used for the same type of procedure throughout the day or may be used  
371 for a variety of procedures. Therefore, the sonographer should select the transducer based on the  
372 intended use. The facility's policies should address whether to have appropriately disinfected transducers  
373 available in storage or to reprocess transducers as needed.

#### 374 6.2. Reprocessing Time

375 Consider the length of each patient procedure and the reprocessing time. If the reprocessing time is more  
376 than the amount of time available between scans, the facility may need additional transducer inventory.  
377 It may be helpful to map out the patient-to-patient workflow, including reprocessing, to identify potential  
378 efficiency gains. For example, it may be possible to conduct reprocessing in parallel to the patient change-  
379 over process.

### 380 6.3. Reprocessing Location

381 After the procedure, immediately remove the transducer cover, excess gel, and other contaminated items  
382 (e.g., gowns, sheets) and dispose of them in a designated, approved receptacle. The transducer can  
383 potentially be reprocessed in the exam room, if the cleaning and disinfection processes are suitable for  
384 use in that environment and a dirty-to-clean workflow is established.<sup>12</sup>

385 If the transducer cannot be safely reprocessed in the exam room, transport the transducer in a designated,  
386 approved container to a separate room for reprocessing and then return the transducer in a designated,  
387 approved clean or sterile transport container, as appropriate. Handle and transport the transport  
388 containers in a manner to prevent contamination of the transducer, other equipment, and the facility.  
389 Disinfect transport containers and any transport carts. Clearly mark designated, approved containers as  
390 clean or dirty with a biohazard symbol.

### 391 6.4. Compatibility

392 The facility must have the capability and capacity to adequately clean and reprocess the transducer.  
393 Consult the manufacturer's IFU or other guidance on use, handling, cleaning, disinfection or sterilization,  
394 transport, and storage of the manufacturer's equipment before purchasing. If an entity other than the  
395 manufacturer has repaired the transducer, ensure the manufacturer's IFU for cleaning and reprocessing  
396 is still valid.

### 397 6.5. Cost, Complexity, and Safety

398 Before adopting a reprocessing workflow, consider the total cost of reprocessing including equipment,  
399 consumables, personnel, time, personal protective equipment, and turnover time. It is also important to  
400 look at how safe, reliable, and reproducible the process is for the patient, sonographer, and transducer.  
401 <sup>1,2</sup> Additionally, consider how reprocessing time might impact patient throughput.

### 402 6.6. Establishing Policies and Standard Operating Procedures (SOPs)

403 The facility should have written reprocessing policies and standard operating procedures (SOPs) that are  
404 specific to the types of procedures, transducers, ancillary equipment, clinical settings, and disinfection or  
405 sterilization requirements. Align the policies and SOPs with current regulations, guidelines, standards, and  
406 transducer manufacturer's IFUs. Conduct ongoing risk assessments and review of policies and SOPs and  
407 update accordingly.

### 408 6.7. Personnel

409 Personnel assigned to perform transducer reprocessing (typically the sonographer) should undergo  
410 documented competency-based training and assessment on transducer reprocessing at least annually.  
411 Policies should define the roles and responsibilities of the personnel assigned to manage and ensure  
412 compliance with procedures and reprocessing requirements.<sup>1,2</sup>

### 413 6.8. Evaluation and Quality Improvement

414 A process that monitors infection prevention and control practices related to ultrasound use and  
415 reprocessing workflow should be in place for each clinical setting. The process should reflect an  
416 assessment of risks with the procedure to both patients and sonographers. The process should include  
417 methods for observation, performance measurement, intervention, feedback, and documentation to  
418 identify practice gaps. Report process results as part of a continuous quality and performance  
419 improvement approach.

420 Maintenance of the transducer and ancillary equipment should follow the same process of risk  
421 assessment, performance measurement, intervention, feedback, and documentation. If equipment  
422 damage is identified, such as a transducer with a crack, abrasion, or tear, there should be processes in  
423 place to promptly identify the damage, remove the equipment from use, and document the damage and  
424 repair. Damaged equipment may harbor pathogens, tear transducer covers, or impact the ability of the  
425 sonographer to safely and accurately perform the procedure.

426 **7. References**

- 427 1. Rutala WA, Weber DJ, Healthcare Infection Control Practices Advisory Committee (HICPAC), Centers  
428 for Disease Control and Prevention . USA. Guideline for Disinfection and Sterilization in Healthcare  
429 Facilities. 2008 (Updated 15 February 2017). Available at:  
430 <https://www.cdc.gov/infectioncontrol/pdf/guidelines/disinfection-guidelines.pdf>.
- 431 2. ST58:2013 AA. American National Standards Institute (ANSI) and Association for the Advancement  
432 of Medical Instrumentation (AAMI). ANSI/AAMI ST58:2013. Chemical sterilization and high-level  
433 disinfection in health care facilities.
- 434 3. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for  
435 Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER), Office of  
436 Regulatory Affairs (ORA). Guidance for Industry: Sterile Drug Products Produced by Aseptic  
437 Processing - Current Good Manufacturing Practice. United States Food and Drug Administration.  
438 September 2004.
- 439 4. TIR34 A-. Association for the Advancement of Medical Instrumentation (AAMI). AAMI TIR34:2014.  
440 Water for the reprocessing of medical devices. AAMI Technical Information Reports. 2014.
- 441 5. Spaulding EH. Chemical disinfection of medical and surgical materials. In: Lawrence C, Block SS, eds.  
442 Disinfection, sterilization, and preservation. Philadelphia: Lea & Febiger, 1968:517-31.
- 443 6. American Institute for Ultrasound in Medicine (AIUM). Guidelines for Cleaning and Preparing  
444 External- and Internal-Use Ultrasound Probes Between Patients, Safe Handling, and Use of  
445 Ultrasound Coupling Gel. Updated 3 November 2018.
- 446 7. Health Service Executive (HSE) Quality Improvement Division – Decontamination Safety Programme.  
447 Ireland, January 2017. HSE Guidance for Decontamination of Semi-critical Ultrasound Probes; Semi-  
448 invasive and Non-invasive Ultrasound Probes. Document: QPSD-GL-028-1.
- 449 8. Health Facilities Scotland, NHS National Services Scotland, Health Protection Scotland. Scotland,  
450 March 2016. NHS Scotland Guidance for Decontamination of Semi-Critical Ultrasound Probes; Semi-  
451 invasive and Non-invasive Ultrasound Probes. Document: HPS/HFS Version 1.0.
- 452 9. Abramowicz JS, Evans DH, Fowlkes JB, Maršal K, terHaar G. Guidelines for cleaning transvaginal  
453 ultrasound transducers between patients. *Ultrasound in Med & Biol*. 2017;43(5):1076-1079. Doi:  
454 10.1016/j.ultrasmedbio.2017.01.002
- 455 10. Nyhsen CM, Brady A, D’Onofrio M, Sidhu P, Humphreys H, Nicolau C, Gangi A, Koerner RJ, Mostbeck  
456 G, Claudon M. Infection prevention and control in ultrasound - best practice recommendations  
457 from the European Society of Radiology Ultrasound Working Group. *Insights Imaging*. 2017; 8(6): 523-  
458 535.
- 459 11. European Committee for Medical Ultrasound Safety (ECMUS). Best practice recommendations for  
460 cleaning and disinfection of ultrasound transducers whilst maintaining transducer integrity. 2017.  
461 ECMUS Editors: C Kollmann & K Salvesen.
- 462 12. Australasian Society for Ultrasound in Medicine (ASUM), Australasian College for Infection  
463 Prevention and Control (ACIPC). Guidelines for reprocessing ultrasound transducers. *Aust J of*  
464 *Ultrasound in Med*. 2017;20(1):30-40. Doi: 10.1002/ajum.12042
- 465 13. Seki M, Machida H, Yamagishi Y, Yoshida H, Tomono K. Nosocomial outbreak of multidrug-resistant  
466 pseudomonas aeruginosa caused by damaged transesophageal echocardiogram probe used in  
467 cardiovascular surgical operations. *J Infect Chemother*. 2013;19(4):677-681. Doi: 10.1007/s10156-  
468 012-0542-0
- 469 14. Shaban RZ, Maloney S, Gerrard J, et al. Outbreak of health care-associated burkholderia cenocepacia  
470 bacteremia and infection attributed to contaminated sterile gel used for central line insertion under  
471 ultrasound guidance and other procedures. *Am J Infect Control*. 2017;45(9):954-958. Doi:  
472 10.1016/j.ajic.2017.06.025



- 473 15. Paz A, Bauer H, Potasman I. Multiresistant pseudomonas aeruginosa associated with contaminated  
474 transrectal ultrasound. *J Hosp Infect.* 2001;49(2):148-149. Doi: 10.1053/jhin.2001.1056
- 475 16. Ferhi K, Roupret M, Mozer P, Ploussard G, Haertig A, de La Taille A. Hepatitis c transmission after  
476 prostate biopsy. *Case Rep Urol.* 2013;2013:797248. Doi: 10.1155/2013/797248
- 477 17. Keizur JJ, Lavin B, Leidich RB. Latrogenic urinary tract infection with pseudomonas cepacia after  
478 transrectal ultrasound guided needle biopsy of the prostate. *J Urol.* 1993;149(3):523-526. Doi:  
479 10.1016/s0022-5347(17)36135-9
- 480 18. Medicines and Healthcare Products Regulatory Agency (UK). Medical Device Alert. 28 June 2012.  
481 Reusable transoesophageal echocardiography, transvaginal and transrectal ultrasound probes  
482 (transducers) Document: MDA/2012/037. 2012.
- 483 19. Abdelfattah R, Aljumaah S, Alqahtani A, Althawadi S, Barron I, Almofada S. Outbreak of burkholderia  
484 cepacia bacteraemia in a tertiary care centre due to contaminated ultrasound probe gel. *J Hosp  
485 Infect.* 2018;98(3):289-294. Doi: 10.1016/j.jhin.2017.09.010
- 486 20. US Food and Drug Administration (FDA). UPDATE on Bacteria Found in Other-Sonic Generic  
487 Ultrasound Transmission Gel Poses Risk of Infection. FDA Safety Communication. 2012.
- 488 21. The Joint Commission (TJC). Improperly sterilized or HLD equipment – a growing problem. TJC Quick  
489 Safety. May 2017. Issue 33.
- 490 22. Centers for Disease Control and Prevention (CDC). (2012). Pseudomonas aeruginosa Respiratory  
491 Tract Infections Associated with Contaminated Ultrasound Gel Used for Transesophageal  
492 Echocardiography — Michigan. Morbidity and Mortality Weekly Report No. 61(15):262-264. 2012.
- 493 23. Buescher DL, Mollers M, Falkenberg MK, Amler S, Kipp F, Burdach J, Klockenbusch, W, Schmitz R.  
494 Disinfection of transvaginal ultrasound probes in a clinical setting: comparative performance of  
495 automated and manual reprocessing methods. *Ultrasound Obstet Gynecol.* 2016;47(5): 646-651.
- 496 24. The Joint Commission (TJC). High-Level Disinfection (HLD) and Sterilization BoosterPak. 2016.  
497 Available from: [http://www.jointcommission.org/assets/1/6/TJC\\_HLD\\_BoosterPak.pdf](http://www.jointcommission.org/assets/1/6/TJC_HLD_BoosterPak.pdf).
- 498 25. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for  
499 Devices and Radiological Health (CDRH), Office of Office of Device Evaluation, Center for Biologics  
500 Evaluation and Research (CBER). Reprocessing Medical Devices in Health Care Settings: Validation  
501 Methods and Labeling. Guidance for Industry and Food and Drug Administration Staff. 2015.
- 502 26. U.S. Department of Health and Human Services, Food and Drug Administration (FDA), Center for  
503 Devices and Radiological Health (CDRH). Marketing Clearance of Diagnostic Ultrasound Systems and  
504 Transducers - Guidance for Industry and Food and Drug Administration Staff. 2019.
- 505 27. Westerway SC, Basseal JM, Brockway A, Hyett JA, Carter DA. Potential infection control risks  
506 associated with ultrasound equipment - a bacterial perspective. *Ultrasound Med Biol.*  
507 2017;43(2):421-426. Doi: 10.1016/j.ultrasmedbio.2016.09.004
- 508 28. Memorandum WHT. WHTM 01-06 - Decontamination of flexible endoscopes Part C: Operational  
509 management (including guidance on non-channelled endoscopes and ultrasound probes). NHS  
510 Wales Shared Services Partnership – Specialist Estates Services; 2014. p. 74.
- 511 29. Ofstead CL, Wetzler HP, Snyder AK, Horton RA. Endoscope reprocessing methods: a prospective  
512 study on the impact of human factors and automation. *Gastroenterology Nurs.* 2010;33(4):304-11.  
513 Doi: 10.1097/SGA.0b013e3181e9431a.
- 514 30. Ngu A, McNally G, Patel D, Gorgis V, Leroy S, Burdach J. Reducing transmission risk through high-  
515 level disinfection of transvaginal ultrasound transducer handles. *Infect Control Hosp Epidemiol* 2015;  
516 36(5):581–584. Doi: 10.1017/ice.2015.12
- 517 31. Ferranti G, Marchesi I, Favale M, Borella P, Bargellini A. Aetiology, source and prevention of  
518 waterborne healthcare-associated infections: a review. *J Med Microbiol.* 2014;63(Pt 10):1247-1259.  
519 Doi: 10.1099/jmm.0.075713-0



## 520 8. Glossary of Terms and Abbreviations/Acronyms

521 **AAMI:** Association for the Advancement of Medical Instrumentation.

522 **Ancillary Equipment:** Equipment used during the procedure (e.g., cables, keyboards, beds, chairs, IV  
523 poles, oxygen systems, light switches, door knobs/handles).

524 **Bioburden:** The number of bacteria living on an unsterilized transducer or other surface.

525 **CDC:** Centers for Disease Control and Prevention; a federal agency of the United States Department of  
526 Health and Human Services, which is responsible for developing and applying disease prevention and  
527 control to improve the health of the people and reduce the burden of infectious diseases.

528 **Chemical Indicator:** A device for monitoring the sterilization process.

529 **Cleaning:** The removal of visible soil (e.g., organic and inorganic material) from objects and surfaces and  
530 is normally accomplished manually or mechanically using water with detergents or enzymatic products.  
531 Thorough cleaning is essential before HLD and sterilization because inorganic and organic materials that  
532 remain on the surfaces of instruments interfere with the effectiveness of these processes.

533 **Coupling Agent:** See *Gel*.

534 **Critical Water:** Treated water, which has microorganisms and inorganic/organic material removed, used  
535 for the final rinse.

536 **Disinfection:** Thermal or chemical destruction of pathogenic and other types of microorganisms.  
537 Disinfection is less lethal than sterilization because it destroys most recognized pathogenic  
538 microorganisms but not necessarily all microbial forms (e.g., bacterial spores).

539 **Disinfectant:** Normally a chemical agent (but sometimes a physical agent) that destroys disease-causing  
540 pathogens or other harmful microorganisms. The EPA groups disinfectants by product label claims of  
541 “limited,” “general,” or “hospital” disinfection.

542 **EHR:** Electronic Health Record; an electronic record of patient health information generated from one or  
543 more encounters in any healthcare delivery setting.

544 **Facility:** For purposes of these guidelines, a facility is a clinical setting where transducers are used to  
545 generate medical images, including but not limited to: hospital, clinic, physician’s office, dedicated  
546 imaging lab, ambulance, etc.

547 **FDA:** Federal Drug Administration; a federal agency of the United States Department of Health and Human  
548 Services, which is responsible for protecting and promoting public health; among other areas of  
549 responsibility, the FDA is responsible for the control and supervision of medical devices including the  
550 transducer and ancillary equipment.

551 **Gel:** An acoustic coupling agent used between the transducer and the patient’s skin to facilitate  
552 ultrasound transmission and reception.

553 **Glutaraldehyde:** A disinfectant used for sterilization of heat-sensitive equipment and instruments; it is a  
554 broad-spectrum microbicide effective against vegetative bacteria, fungi, and viruses, is sporicidal, and  
555 used as a liquid sterilant with an extended exposure time.

556 **HLD: High-Level Disinfection;** removal of all microorganisms, except bacterial endospores (a small number  
557 may remain).

558 **Hydrogen Peroxide:** A chemical used against a wide range of microorganisms, including bacteria, yeasts,  
559 fungi, viruses, and spores; used in conjunction with or blended with other chemicals such as peracetic  
560 acid.

561 **Intact Skin:** Skin that is completely unbroken (e.g., no skin cut, abrasion, dermatitis, needle puncture).

562 **IFU: Instructions For Use;** typically provided in print or online by the manufacturer or supplier, and may  
563 include guidance for the proper use, cleaning, disinfection or sterilization, transport, storage, and repair.

564 **LLD: Low-Level Disinfection;** the inactivation of all vegetative bacteria, enveloped viruses, some non-  
565 enveloped viruses, and most fungi.

566 **Mucous Membranes:** Membranes which produce mucus and line cavities or surfaces of the body that  
567 open to the external environment, such as the digestive tract, respiratory passages, and genitourinary  
568 tract.

569 **Non-Intact Skin:** Unhealthy (e.g., dermatitis, rash, psoriasis) or broken skin (e.g., skin cut, abrasion,  
570 previous needle puncture).

571 **OPA: Ortho-phthalaldehyde;** a chemical approved for high-level disinfection of medical equipment; its  
572 use requires safety precautions, specialized equipment, and proper ventilation to avoid respiratory injury  
573 or skin reactions; use on transducers should comply with the manufacturer’s IFU.

574 **Peracetic Acid:** A highly biocidal oxidizer disinfectant that oxidizes the outer cell membranes of  
575 microorganisms used to deactivate a large variety of pathogenic microorganisms, viruses, and spores.

576 **Probe:** An informal term sometimes used to refer to the transducer (*see Transducer*).


577 **Procedure:** A sonography procedure or examination (also known as sonogram, sonographic examination,  
578 ultrasound procedure, ultrasound examination, etc.) that can help diagnose a variety of medical  
579 conditions, assess illnesses in tissues and organs, or evaluate injury; the procedure may be performed in  
580 a variety of clinical settings, including but not limited to a hospital, at the patient’s bed-side, clinic,  
581 dedicated specialty imaging lab (e.g., cardiac, vascular), or by mobile service (e.g., performed at a home,  
582 a nursing home); sonography-guidance may also be used with invasive procedures such as biopsies, etc.

583 **Reprocessing:** Procedure to prepare the transducer and any ancillary equipment (e.g., keyboards, beds,  
584 chairs, IV poles, oxygen systems, light switches, door knobs/handles) for reuse, including: cleaning,  
585 disinfection or sterilization, transport, and storage.

586 **Reprocessing Area:** Area of a healthcare facility designated for collection, retention, and cleaning of soiled  
587 and/or contaminated items.


- 588 **RFID:** Radio Frequency Identification; uses electromagnetic fields to automatically identify and track tags  
589 attached to medical devices, etc.
- 590 **SOP:** Standard Operating Procedures; step-by-step instructions to assist in carrying out complex  
591 processes, such as reprocessing the transducer.
- 592 **Spaulding Classification:** A classification system that determines the disinfection and sterilization  
593 requirements for medical devices based on the level of infection risk associated with use.
- 594 **Sterile Tissues:** Body sites, cavities, or tissues that are endogenously free from all living organisms. Sterile  
595 tissues include the vascular system, joints and joint spaces, other internal body fluids such as blood or  
596 synovial fluid, the vasculature and internal body organs, peritoneum, and retroperitoneum.
- 597 **Sterility Assurance Level (SAL):** The probability that a single item (e.g., transducer) subjected to  
598 sterilization, nevertheless remains nonsterile; A SAL of  $10^{-6}$  is the generally accepted level for sterilization  
599 procedures, (i.e., a probability of not more than one viable microorganism in one million sterilized items).
- 600 **Sterilization:** The destruction or inactivation of microorganisms, which minimizes infection transmission  
601 risk; choice of disinfection/sterilization level depends on the Spaulding Classification of the transducer  
602 and ancillary equipment, which is based on the intended use in the next procedure; some healthcare  
603 professionals and literature refer to “disinfection” as “sterilization”
- 604 **Storage:** An area or cabinet designed to protect transducers, and any ancillary equipment from damage  
605 or contamination; storage should be consistent with the manufacturer’s recommendations and other  
606 requirements.
- 607 **Transducer:** A medical device that sends sound waves into a body and receives the returning echoes from  
608 tissues, structures, or spaces, which are analyzed by a computer to generate a medical image.
- 609 **Transducer Cover:** An FDA cleared barrier that covers the transducer to prevent contamination and  
610 transmission of infection or disease.

# Appendix 1: Preparing for the Next Sonography Procedure



HLD = High Level Disinfection; LLD = Low Level Disinfection; Cover = Transducer Cover

## Appendix 2: Reprocessing the Ultrasound Transducer and Ancillary Equipment



HLD = High Level Disinfection; LLD = Low Level Disinfection; Cover = Transducer Cover; IFU = Instructions for use

# Appendix 3:

## Sonography Procedures: Transducer Disinfection and Infection Control

Note that the expected Spaulding Classification for a sonography procedure could change upon patient condition (e.g., has open wound or infection in the scan area) or during the procedure (e.g., blood is present).

SONOGRAPHY PROCEDURES	EXPECTED: BEFORE PROCEDURE			KEY: ✓* = Allowed/Preferred; ✓ = Allowed; ⊘ = Not Allowed								
	ASSESS RISK THAT THE TRANSDUCER (with or without a transducer cover) WILL COME IN CONTACT WITH:			SPAULDING CLASSIFICATION	BEST PRACTICE							
	Intact Skin	Mucous Membrane or Non-Intact Skin	Sterile Tissue or Blood		TRANSDUCER REPROCESSING			TRANSDUCER COVER		COUPLING AGENT/GEL		
PROCEDURE DESCRIPTION					Clean & Sterile Process	Clean & HLD Process	Clean & LLD Process	Sterile	Non-Sterile	Sterile	Non-Sterile	
<b>HEAD/NECK</b>												
Neck, Thyroid/Parathyroid	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Neonatal Brain (Echocardiography)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Ophthalmic (A-scan)		X		Semi-Critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Ophthalmic (A-scan/B-scan)		X		Semi-Critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Ophthalmic (B-scan)		X		Semi-Critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Ophthalmic Anterior Segment (immersion B-scan)		X		Semi-Critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Ophthalmic Biometry (A-scan w/ intraocular lens power calc)		X		Semi-Critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Ophthalmic Biometry (A-scan w/ lens power calc)		X		Semi-Critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Ophthalmic Biometry (A-scan)		X		Semi-Critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Ophthalmic Corneal Pachymetry		X		Semi-Critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Ophthalmic Foreign Body		X		Semi-Critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Spinal Canal & Contents	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
<b>CHEST/BREAST</b>												
Breast w/ axilla (unilateral, complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Breast w/ axilla (unilateral, limited)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Chest (includes mediastinum, chest wall, and upper back)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
<b>EXTREMITIES</b>												
Infant Hips (dynamic, physician manipulation)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Infant Hips (limited, static)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Non-Vascular Extremity (complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Non-Vascular Extremity (limited)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
<b>ABDOMEN</b>												
Abdomen (complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Abdomen (limited)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Abdomen Elastography	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Aorta (limited, AAA screening)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Renal Retroperitoneal (complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	

SONOGRAPHY PROCEDURES	EXPECTED: BEFORE PROCEDURE			KEY: ✓* = Allowed/Preferred; ✓ = Allowed; ⊘ = Not Allowed								
PROCEDURE DESCRIPTION	ASSESS RISK THAT THE TRANSDUCER (with or without a transducer cover) WILL COME IN CONTACT WITH:			SPAULDING CLASSIFICATION	BEST PRACTICE							
	Intact Skin	Mucous Membrane or Non-Intact Skin	Sterile Tissue or Blood		TRANSDUCER REPROCESSING			TRANSDUCER COVER		COUPLING AGENT/GEL		
					Clean & Sterile Process	Clean & HLD Process	Clean & LLD Process	Sterile	Non-Sterile	Sterile	Non-Sterile	

### ABDOMEN (continued)

Renal Retroperitoneal (limited)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Retroperitoneal - Transplanted Kidney (w/ Duplex Doppler)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Scrotum & Testicles	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Transrectal		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓
Transrectal, Prostate		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓

### NON-OBSTETRICAL PELVIC

Pelvic (non-OB, transvaginal)		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓
Sonohysterography w/ Doppler (non-OB, transvaginal)		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓
Pelvic (non-OB, complete, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pelvic (non-OB, limited or follow-up, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*

### OBSTETRIC

Fetal Biophysical Profile (w/ non-stress testing)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Fetal Biophysical Profile (w/o non-stress testing)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Fetal Middle Cerebral Artery (Doppler velocimetry)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Fetal Umbilical Artery (Doppler velocimetry)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant < 14 weeks (single/first, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant < 14 weeks (additional gestation, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant > 14 weeks (single/first, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant > 14 weeks (additional gestation, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant (Follow-up transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant (limited, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant (limited, transvaginal)		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓
Pregnant (transvaginal)		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓
Pregnant w/ Detailed Fetal Anatomic Exam (single/first gestation, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant w/ Detailed Fetal Anatomic Exam (additional gestation, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant w/ First Trim Fetal Nuchal Translucency (single/first gestation, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant w/ First Trim Fetal Nuchal Translucency (additional gestation, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Pregnant w/ First Trim Fetal Nuchal Translucency (single/first gestation, transvaginal)		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓

SONOGRAPHY PROCEDURES	EXPECTED: BEFORE PROCEDURE			KEY: ✓* = Allowed/Preferred; ✓ = Allowed; ⊘ = Not Allowed								
PROCEDURE DESCRIPTION	ASSESS RISK THAT THE TRANSDUCER (with or without a transducer cover) WILL COME IN CONTACT WITH:			SPAULDING CLASSIFICATION	BEST PRACTICE							
	Intact Skin	Mucous Membrane or Non-Intact Skin	Sterile Tissue or Blood		TRANSDUCER REPROCESSING			TRANSDUCER COVER		COUPLING AGENT/GEL		
					Clean & Sterile Process	Clean & HLD Process	Clean & LLD Process	Sterile	Non-Sterile	Sterile	Non-Sterile	
<b>OBSTETRIC (continued)</b>												
Pregnant w/ First Trim Fetal Nuchal Translucency (additional gestation, transvaginal)		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓	
<b>ECHOCARDIOGRAPHY (FETAL)</b>												
Fetal Doppler Echocardiography (complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Fetal Doppler Echocardiography (follow-up or repeat)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Fetal Echocardiography (2D)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Fetal Echocardiography (follow-up or repeat)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
<b>ECHOCARDIOGRAPHY (PEDIATRIC/ADULT)</b>												
Doppler Echocardiography (velocity mapping)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Doppler Echocardiography (complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Doppler Echocardiography (limited or follow-up)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Echocardiography (complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Echocardiography (limited)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Echocardiography (w/o Doppler/color flow)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Echocardiography (congenital, complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Echocardiography (congenital, follow-up or limited)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Stress Echocardiography	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Stress Echocardiography w/ ECG	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
<b>VASCULAR</b>												
Abdominal Duplex Arterial/Venous (complete, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Abdominal Duplex Arterial/Venous (complete, transvaginal)		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Abdominal Duplex Vascular (limited, transabdominal)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Abdominal Duplex Vascular (limited, transvaginal)		X		Semi-critical	optional	✓*	⊘	✓*	✓	✓*	✓	
Carotid Intima-Media Thickness (complete, bilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Carotid Doppler (limited, unilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Carotid Duplex (complete, bilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Duplex Aorta, IVC, iliac, or bypass grafts (complete, bilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Duplex Aorta, IVC, iliac, or bypass grafts (limited, unilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Duplex Arterial/Venous Penile (complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	
Duplex Arterial/Venous Penile (follow-up or limited)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*	



SONOGRAPHY PROCEDURES	EXPECTED: BEFORE PROCEDURE			KEY: ✓* = Allowed/Preferred; ✓ = Allowed; ⊘ = Not Allowed								
PROCEDURE DESCRIPTION	ASSESS RISK THAT THE TRANSDUCER (with or without a transducer cover) WILL COME IN CONTACT WITH:			SPAULDING CLASSIFICATION	BEST PRACTICE							
	Intact Skin	Mucous Membrane or Non-Intact Skin	Sterile Tissue or Blood		TRANSDUCER REPROCESSING			TRANSDUCER COVER		COUPLING AGENT/GEL		
					Clean & Sterile Process	Clean & HLD Process	Clean & LLD Process	Sterile	Non-Sterile	Sterile	Non-Sterile	

### VASCULAR (continued)

Duplex Lower Extremity Veins (complete, bilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Duplex Upper Extremity Veins (complete, bilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Duplex Lower Extremity Veins (limited, unilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Duplex Upper Extremity Veins (limited, unilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Duplex Hemodialysis Access	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Duplex Lower Extremity Arterial (complete, unilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Duplex Lower Extremity Arterial (limited, unilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Duplex Upper Extremity Arterial (complete, bilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Duplex Upper Extremity Arterial (limited, unilateral)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Transcranial Doppler Intracranial Artery (vasoreactivity)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Transcranial Doppler Intracranial Artery (complete)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Transcranial Doppler Intracranial Artery (limited)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Transcranial Doppler Intracranial Artery (emboli detection w/ contrast)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Transcranial Doppler Intracranial Artery (emboli detection w/o contrast)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*

### GUIDANCE

Abdominal Paracentesis			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Amniocentesis			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Arterial Pseudoaneurysms or Arteriovenous Fistulae			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Arthrocentesis (intermediate joint or bursa)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Arthrocentesis (major joint or bursa)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Arthrocentesis (major joint or bursa)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Breast Biopsy, Localization Device (first lesion)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Breast Biopsy, Localization Device (additional lesion)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Breast, Localization Device (first lesion)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Breast, Localization Device (additional lesion)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Chorionic Villus Sampling			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Endomyocardial Biopsy			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Endovenous Ablation w/ laser (first vein)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Endovenous Ablation w/ laser (additional vein)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘

SONOGRAPHY PROCEDURES	EXPECTED: BEFORE PROCEDURE			KEY: ✓* = Allowed/Preferred; ✓ = Allowed; ⊘ = Not Allowed								
PROCEDURE DESCRIPTION	ASSESS RISK THAT THE TRANSDUCER (with or without a transducer cover) WILL COME IN CONTACT WITH:			SPAULDING CLASSIFICATION	BEST PRACTICE							
	Intact Skin	Mucous Membrane or Non-Intact Skin	Sterile Tissue or Blood		TRANSDUCER REPROCESSING			TRANSDUCER COVER		COUPLING AGENT/GEL		
					Clean & Sterile Process	Clean & HLD Process	Clean & LLD Process	Sterile	Non-Sterile	Sterile	Non-Sterile	

### GUIDANCE (continued)

Endovenous Ablation w/ Radiofrequency (first vein)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Endovenous Ablation w/ Radiofrequency (additional vein)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Fine Needle Aspiration Biopsy (first lesion)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Fine Needle Aspiration Biopsy (additional lesion)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Intraoperative			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Intrauterine Fetal Transfusion or Cordocentesis			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Needle Placement (e.g., biopsy, aspiration, injection, localization device)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Ova Aspiration (transvaginal)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Penile Injection with Vasoactive Agent			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Pericardiocentesis			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Peritoneal Lavage			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Pleural Drainage			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Radiation Therapy Placement			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Thoracentesis			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Tissue Ablation			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Vascular Access			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘

### OTHER

Contrast (non-cardiac, initial lesion)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Contrast (non-cardiac, additional lesion)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Elastography (first lesion)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Elastography (additional lesion)	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Assessment of Subclinical Atherosclerosis	X			Non-Critical	optional	optional	✓*	optional	optional	optional	✓*
Cervical or Thoracic injection (single level)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Cervical or Thoracic Transforaminal Epidural Injection (single level)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘
Lumbar or Sacral Transforaminal Epidural Injection (single level)			X	Critical	✓*	✓	⊘	✓*	⊘	✓*	⊘